Written Question · S1W-08411 · Session 1
Whether beta interferon will continue to be made available to multiple sclerosis patients in Scotland in the light of the announcement by t…
The question
To ask the Scottish Executive whether beta interferon will continue to be made available to multiple sclerosis patients in Scotland in the light of the announcement by the National Institute for Clinical Excellence in England and Wales.
The answer
The National Institute for Clinical Excellence (NICE) has made no announcement about Beta Interferon as its appraisal process is still running. NICE have sent their draft conclusions for comment in strict confidence to a number of interested parties, including patient groups. The Scottish Executive has not received the draft conclusions from NICE and, until the process under way is complete, we cannot speculate on what might be in the draft.At present local Drug and Therapeutic Committees provide advice to clinicians in their health board on the use of Beta Interferon in the treatment of multiple sclerosis. To provide a single national focus for this advice, I recently wrote to the Health Technology Board asking them to provide advice on the clinical and cost-effectiveness of Beta Interferon as a treatment for multiple sclerosis as an early priority.
In the Official Report
No contribution in the Official Report cites S1W-08411 by reference.